MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Royal DSM N.V.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DSM Completes Acquisition of Tortuga - Royal DSM announces that it has completed the acquisition of Tortuga Companhia Zootécnica Agrária (Tortuga) - DSM.com
DSM Completes Acquisition of Tortuga

 

NewswireToday - /newswire/ - Heerlen, Netherlands, 2013/04/08 - Royal DSM announces that it has completed the acquisition of Tortuga Companhia Zootécnica Agrária (Tortuga) - DSM.com. Euronext: DSM KON

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Royal DSM, the global Life Sciences and Materials Sciences company, announces today that it has completed the acquisition of Tortuga Companhia Zootécnica Agrária (Tortuga), a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million (BRL 1,160 million). The acquisition was announced on 8 August 2012.

Tortuga, the Brazilian market leader in organic trace minerals for animal nutrition and health with a focus on pasture raised beef and dairy cattle, strengthens DSM’s position in nutritional supplements and additives for ruminants and our presence in Brazil, one of the leading ruminant markets in the world.

Tortuga also broadens DSM’s animal nutrition ingredients portfolio with the highly attractive organic trace minerals, while offering many value creating synergies. Tortuga is headquartered in Sao Paulo, Brazil with approximately 1,200 employees.

Stephan Tanda, Member of the DSM Managing Board and responsible for the Nutrition cluster, commented: “Completing the acquisition of Tortuga is a major step in the implementation of DSM’s Nutrition strategy. Our attention is now fully focused on ensuring a smooth integration of the Tortuga business in a timely and efficient manner, with business continuity and customer satisfaction as key priorities for us while we welcome Tortuga’s 1,200 employees to DSM.”

Full scale integration will now begin. A dedicated integration team consisting of both DSM and Tortuga representatives will work diligently to assess the best way to execute the integration while focusing on future synergy generation.

DSM Investor Relations
Dave Huizing
P: +31 (0)45 578 2864 - E: investor.relations[.]dsm.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Royal DSM N.V.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DSM Completes Acquisition of Tortuga

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Herman Betten - DSM.com 
+31(0)45 5782017 media.relations[.]dsm.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Royal DSM N.V. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)